title: Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer.
abstract: OBJECTIVE
  According to a few recent reports on the long-term clinical outcome of gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma (MALT lymphoma); localized gastric MALT lymphoma generally has a favorable prognosis. However, the risk of metachronous gastric cancer has not been evaluated. In this study, we analyzed long-term outcomes of localized gastric MALT lymphoma including the incidence of metachronous gastric cancer.
  
  
  METHODS
  Between April 1996 and May 2008, 60 patients (31 men and 29 women; mean age 58.1 years) with localized gastric MALT lymphoma (stage I and II(1) according to Lugano classification) were analyzed retrospectively.
  
  
  RESULTS
  Forty-eight patients (82.6%) achieved complete remission by eradication therapy. Radiation therapy was conducted on eight patients as second-line treatment, and all of them achieved remission. The median follow-up period was 76 months (range, 12-157 months). One patient had local relapse after remission for 5 years and three patients developed early gastric cancer without recurrence of lymphoma (5%). All of the three gastric cancers appeared in the same areas where MALT lymphoma had been eradicated.
  
  
  CONCLUSIONS
  Eradication therapy and radiation therapy for localized gastric MALT lymphoma have a favorable long-term outcome, though regular follow-up endoscopy should be performed for detecting metachronous early gastric cancer.
authors.affiliation: Division of Endoscopy, Hokkaido University Hospital, Sapporo, Japan. onosho@med.hokudai.ac.jp
authors.forename: Shouko
authors.initials: S
authors.lastname: Ono
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Kato
authors.forename: Kikuko
authors.initials: K
authors.lastname: Takagi
authors.forename: Junichi
authors.initials: J
authors.lastname: Kodaira
authors.forename: Kanako
authors.initials: K
authors.lastname: Kubota
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Matsuno
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Komatsu
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005743:Gastrectomy; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D018442:Lymphoma, B-Cell, Marginal Zone / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome